Global Krabbe Disease Treatment Market 2018-2022

クラッベ病治療薬の世界市場2018-2022:抗痙攣薬、筋弛緩薬、HSCT、その他

◆タイトル:Global Krabbe Disease Treatment Market 2018-2022
◆商品コード:IRTNTR20609
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年2月5日
◆ページ数:104
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、クラッベ病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、クラッベ病治療薬の世界市場規模及び予測、地域別分析/市場規模、主要国別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。Technavio社はクラッベ病治療薬の世界市場が2018-2022年期間中に年平均7.24%成長すると予測しています。当レポート上に記載されている主な企業は、GlaxoSmithKline、Johnson & Johnson、Novartis等です。

About Krabbe Disease Treatment
Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern.

Technavio’s analysts forecast the global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global krabbe disease treatment market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Krabbe Disease Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Johnson & Johnson
• Novartis

[Market driver]
• Special drug designation
• For a full, detailed list, view our report

[Market challenge]
• Limited patient pool for clinical trials
• For a full, detailed list, view our report

[Market trend]
• Emergence of pharmacological chaperone therapy
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline
• Types of Krabbe disease

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
• Comparison by therapy
• Global Krabbe disease treatment market by anticonvulsants
• Global Krabbe disease treatment market by muscle relaxants
• Global Krabbe disease treatment market by HSCT
• Global Krabbe disease treatment market by others
• Market opportunity by therapy

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Krabbe disease treatment market in Americas
• Krabbe disease treatment market in EMEA
• Krabbe disease treatment market in APAC
• Key leading countries
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Emergence of pharmacological chaperone therapy
• Gene technology in therapy

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline
• Johnson & Johnson
• Novartis

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Types of Krabbe disease
Exhibit 02: Parent market
Exhibit 03: Global rare diseases treatment market: Segmentation
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global Krabbe disease treatment market 2017-2022 ($ millions)
Exhibit 10: Global Krabbe disease treatment market: Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global Krabbe disease treatment market
Exhibit 20: Global Krabbe disease treatment market by therapy 2017-2022 (% share)
Exhibit 21: Comparison by therapy
Exhibit 22: Global Krabbe disease treatment market by anticonvulsants 2017-2022 ($ millions)
Exhibit 23: Global Krabbe disease treatment market by anticonvulsants: Year over year growth 2018-2022 (%)
Exhibit 24: Global Krabbe disease treatment market by muscle relaxants 2017-2022 ($ millions)
Exhibit 25: Global Krabbe disease treatment market by muscle relaxants: Year over year growth 2018-2022 (%)
Exhibit 26: Global Krabbe disease treatment market by HSCT 2017-2022 ($ millions)
Exhibit 27: Global Krabbe disease treatment market by HSCT: Year over year growth 2018-2022 (%)
Exhibit 28: Global Krabbe disease treatment market by others 2017-2022 ($ millions)
Exhibit 29: Global Krabbe disease treatment market by others: Year over year growth 2018-2022 (%)
Exhibit 30: Market opportunity by therapy
Exhibit 31: Customer landscape
Exhibit 32: Global Krabbe disease treatment market by region 2017-2022 (% share)
Exhibit 33: Regional comparison
Exhibit 34: Krabbe disease treatment market in Americas 2017-2022 ($ millions)
Exhibit 35: Krabbe disease treatment market in Americas: Year over year growth 2018-2022 (%)
Exhibit 36: Krabbe disease treatment market in EMEA 2017-2022 ($ millions)
Exhibit 37: Krabbe disease treatment market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 38: Krabbe disease treatment market in APAC 2017-2022 ($ millions)
Exhibit 39: Krabbe disease treatment market in APAC: Year over year growth 2018-2022 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Some long-term complications in HSCT patients
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: GlaxoSmithKline: Overview
Exhibit 49: GlaxoSmithKline: Business segments
Exhibit 50: GlaxoSmithKline: Organizational developments
Exhibit 51: GlaxoSmithKline: Geographic focus
Exhibit 52: Johnson & Johnson: Segment focus
Exhibit 53: GlaxoSmithKline: Key offerings
Exhibit 54: GlaxoSmithKline: Key customers
Exhibit 55: Johnson & Johnson: Overview
Exhibit 56: Johnson & Johnson: Business segments
Exhibit 57: Johnson & Johnson: Organizational developments
Exhibit 58: Johnson & Johnson: Geographic focus
Exhibit 59: Johnson & Johnson: Segment focus
Exhibit 60: Johnson & Johnson: Key offerings
Exhibit 61: Johnson & Johnson: Key customers
Exhibit 62: Novartis: Overview
Exhibit 63: Novartis: Business segments
Exhibit 64: Novartis: Organizational developments
Exhibit 65: Novartis: Geographic focus
Exhibit 66: Novartis: Segment focus
Exhibit 67: Novartis: Key offerings
Exhibit 68: Novartis: Key customers



【掲載企業】

GlaxoSmithKline, Johnson & Johnson, and Novartis.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[クラッベ病治療薬の世界市場2018-2022:抗痙攣薬、筋弛緩薬、HSCT、その他] (Global Krabbe Disease Treatment Market 2018-2022 / IRTNTR20609)販売に関する免責事項
[クラッベ病治療薬の世界市場2018-2022:抗痙攣薬、筋弛緩薬、HSCT、その他] (Global Krabbe Disease Treatment Market 2018-2022 / IRTNTR20609)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆